This Article Abstract Full Text (PDF) All Versions of this Article: 110/18/2824    most recent 01.CIR.0000146339.57154.9Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shai, I. Articles by Ma, J. Search for Related Content PubMed PubMed Citation Articles by Shai, I. Articles by Ma, J. Related Collections Lipids Risk Factors Epidemiology

(Circulation. 2004;110:2824-2830.)
© 2004 American Heart Association, Inc.

Coronary Heart Disease

Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women

Potential Implications for Clinical Guidelines

Iris Shai, RD, PhD; Eric B. Rimm, ScD; Susan E. Hankinson, ScD; Gary Curhan, MD, ScD; JoAnn E. Manson, MD, DrPH; Nader Rifai, PhD; Meir J. Stampfer, MD, DrPH; Jing Ma, MD, PhD

From the Departments of Nutrition (I.S., E.B.R., M.J.S.) and Epidemiology (I.S., E.B.R., S.E.H., J.E.M., M.J.S.), Harvard School of Public Health; Channing Laboratory (E.B.R., S.E.H., G.C., J.E.M., M.J.S., J.M.) and Division of Preventive Medicine (J.E.M., M.J.S.), Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School; and Department of Laboratory Medicine, Children’s Hospital and Harvard Medical School (N.R.), Boston, Mass; and the S. Daniel Abraham International Center for Health and Nutrition, Department of Epidemiology, Ben-Gurion University, Beer-Sheva, Israel (I.S.).

Correspondence to Iris Shai, RD, PhD, Harvard School of Public Health, Department of Epidemiology, 677 Huntington Ave, Boston, MA 02115. E-mail ishai{at}hsph.harvard.edu or irish@bgumail.bgu.ac.il

Received December 15, 2003; de novo received March 25, 2004; revision received June 30, 2004; accepted July 7, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Over the past decade, lipid measurements have been significantly improved and standardized. We evaluated the usefulness of multiple plasma lipid parameters in predicting coronary heart diseases (CHD) among women.

Methods and Results— Among 32 826 women from the Nurses’ Health Study who provided blood samples at baseline, 234 CHD events were documented during 8 years of follow-up. In a nested study, these cases were matched to controls (1:2) for age, smoking, fasting status, and month of blood draw. We estimated the relative risk (RR) for each lipid parameter, adjusted for C-reactive protein, homocysteine, body mass index, family history, hypertension, diabetes, postmenopausal hormone use, physical activity, alcohol intake, and blood draw parameters. The RRs associated with an increase of 1 SD (mg/dL) were as follows: HDL cholesterol (HDL-C) (RR=0.6 [0.5 to 0.8], SD=17), apolipoprotein B₁₀₀ (apoB₁₀₀) (RR=1.7 [1.4 to 2.1], SD=32), LDL cholesterol (LDL-C) (RR=1.4 [1.1 to 1.7], SD=36), total cholesterol (TC) (RR=1.4 [1.1 to 1.6], SD=40), and triglycerides (RR=1.3 [1.0 to 1.5], SD=80). Among the lipid indexes, the RRs were: apoB₁₀₀/HDL-C (RR=1.7 [1.4 to 2.1], SD=1.0), TC/HDL-C (RR=1.6 [1.3 to 1.9], SD=1.3), LDL-C/HDL-C (RR=1.5 [1.3 to 1.9], SD=1.0), and non–HDL-C (RR=1.6 [1.3 to 1.9], SD=42 mg/dL). After simultaneous control for several lipid biomarkers, HDL-C was the primary contributor of the variation in multivariate models (P=0.01), followed by LDL-C (P=0.01), whereas triglycerides and apoB₁₀₀ did not contribute further information. HDL-C–related ratios were the strongest contributors to predicting CHD (P<0.0001).

Conclusions— Lower levels of HDL-C may be a key discriminator of higher CHD events among postmenopausal women. HDL-C–related ratios (such as TC/HDL-C) provide a powerful predictive tool independently of other known CHD risk factors.

Key Words: lipids • coronary disease • women

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Over the past decades, lipid measurements have been significantly improved and standardized. LDL cholesterol (LDL-C) was defined as the primary lipid measurement and the primary target of lipid-lowering therapy for reducing coronary heart disease (CHD) risk by the Adult Treatment Panel III (ATPIII) of the National Cholesterol Education Program.¹ However, the role of HDL cholesterol (HDL-C) as a major predictor of CHD among women, independent of other lipid and inflammation markers, is not well established. The reasons might be historical, perhaps because of inaccuracies in HDL-C measurements in the past² and the relative lack of pharmacological agents for raising HDL-C levels.

Although the contribution of LDL-C to the development of atherosclerosis is accepted,¹ its superiority in predicting CHD is debatable.³ Total apolipoprotein B₁₀₀ (apoB₁₀₀) has been suggested as an alternative measurement.⁴ However, the clinical usefulness of apoB₁₀₀ should be judged against the overall predictive value compared with that of the available measurements.

Lipid indexes such as total cholesterol/HDL-C (TC/HDL-C), LDL-C/HDL-C, or apoB₁₀₀/apoA-I ratio may provide better risk assessment by concurrently accounting for both atherogenic and protective lipid fractions. Non–HDL-C was introduced by ATPIII as an alternative predictor to LDL-C only in patients with hypertriglyceridemia.¹ However, lipid indexes were not indicated as a preferred measurement tool in clinical practice.

We evaluated and compared the usefulness of multiple plasma lipid parameters in predicting future CHD in a prospective nested case-control study among middle-aged women in the Nurses’ Health Study (NHS).

	Methods

Top Abstract Introduction Methods Results Discussion References

 
The NHS and Blood Collection
The NHS was initiated in 1976, with the enrollment of 121 700 female nurses 30 to 55 years old. Since then, follow-up questionnaires have been mailed to the cohort every 2 years to update information on exposures and the occurrence of major illnesses. Between 1989 and 1990, blood samples were collected from 32 826 women. Within 24 hours of collection, 97% of the samples were returned. They were immediately centrifuged, divided into aliquots of plasma, red blood cell, and buffy-coat fractions, and stored in liquid nitrogen. The vials were subjected to 1 freeze/thaw cycle for subaliquots and were thawed a second time for processing at the laboratory.

Assessment of CHD End Points
The end point for this study comprised incident cases of nonfatal myocardial infarction (MI) and fatal CHD that occurred after the blood collection and before May 31, 1998. Women with a previous report of cancer or CHD before the blood collection were excluded. Cases were confirmed if they met the diagnostic criteria of the World Health Organization.⁵ Physicians reviewed medical records blinded to questionnaire information. More than 98% of deaths were identified by systematic searches of the state vital records and the National Death Index.⁶ Fatal CHD was defined as fatal MI confirmed by hospital records or at autopsy or as CHD recorded on the death certificate if no other more likely cause was apparent and the participant was reported to have had CHD previously (for example, by questionnaire or per next of kin). In no instance was the cause on the death certificate accepted without corroboration. Total CHD was defined as nonfatal MI plus fatal CHD. Each case was matched by year of age, year and month of blood draw, fasting status before blood draw (lower/higher than 8 hours), and smoking status (never, past, current) to 2 controls who were free of CHD at the time of the case diagnosis.

Laboratory Methods
Plasma from cases and controls was assayed blindly in the same assay batches. Lipid biomarkers and C-reactive protein (CRP) assays were performed in the laboratory of Dr Nader Rifai (The Children’s Hospital, Boston, Mass), which is certified by the NHLBI/CDC Lipid Standardization program. Total apoB₁₀₀ was measured by an immunoturbidimetric technique on the Hitachi 911 analyzer (Roche Diagnostics). The intra-assay coefficient of variation (CV%) for apoB₁₀₀ was <5.1%. TC was measured enzymatically,⁷ with a CV% <1.7%. Concentrations of triglycerides (TGs)⁸ and HDL-C⁹ were analyzed simultaneously on the Hitachi 911, with CV% of 1.75% and 2.5%, respectively. LDL-C¹⁰ was determined by a homogenous direct method (Genzyme), with a CV% <3.1. CRP was measured by an immunoturbidimetric assay on the Hitachi 911 analyzer (Denka Seiken), with a CV% of 1.4%. Homocysteine was determined by a high-performance liquid chromatography method with a CV% of 2.9%. Quality control data were generated from a fresh sample of women’s or nurses’ samples.

Data Analysis
We compared the characteristics of the case-control groups by Student t test for the continuous variables, ² test for categorical variables, and nonparametric Wilcoxon test for TGs. Among the noncases, we calculated age-adjusted Pearson correlations for apoB₁₀₀ and lipids, physical activity, and body mass index (BMI) and Spearman correlations for apoB₁₀₀, TGs, CRP, and homocysteine, which were not normally distributed.

We used conditional logistic regression models to estimate the associations of lipids with CHD with 95% CIs across quintiles and with 1-SD increases of each lipid parameter. Quintiles were defined according to the parameter distribution among controls. Because of colinearity of total cholesterol, LDL-C, and apoB₁₀₀, these 3 variables could not be entered into a single model simultaneously. We calculated non–HDL-C by subtracting HDL-C from total cholesterol. We calculated the apoB₁₀₀/HDL-C ratio, choosing HDL-C, the main carrier of apoA-1, as its surrogate, because apoA-I was not available in our data. In stepwise unconditional logistic regression, we assessed the residual contribution of each lipid to the prediction model. In this method,¹¹ the lipid parameters are selected into the model in the order of their statistical significance. We assessed the power of the models to discriminate events from nonevents by the C statistic, which is analogous to the area under the receiver operating characteristic (ROC) curve.¹² We used the likelihood ratio test to determine whether the subsequent addition of variables to screening could significantly improve risk prediction models. We further added apoB₁₀₀ or HDL-C to models that included TC, LDL-C, and TGs because the latter 3 lipid parameters are readily available clinically.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Population Characteristics and Intracorrelations
After excluding 24 women who were taking cholesterol-lowering drugs at blood draw and 18 women who were missing apoB₁₀₀ data, we analyzed 234 CHD cases (199 nonfatal, 35 fatal CHD) and 449 controls. Compared with controls, cases were more likely to have diabetes, hypertension, higher BMI, parental MI, lower levels of HDL-C, and higher levels of all other lipid parameters (Table 1). As expected, among the controls, the lipid parameters were intercorrelated (Table 2). ApoB₁₀₀ was correlated with CRP levels, whereas LDL-C was not. TG was the lipid biomarker most associated with nonlipid variables such as CRP, physical activity, and BMI. Alcohol intake and physical activity were associated with higher levels of HDL-C.

View this table: [in this window] [in a new window]   TABLE 1. Baseline Characteristics and Lipid Biomarkers of the Study Population

View this table: [in this window] [in a new window]   TABLE 2. Age-Adjusted Correlations* for Plasma Biomarkers, Physical Activity, BMI, and Alcohol Intake Among the Control Subjects

Association of Lipid Biomarkers and Lipid Indexes With the Risk of CHD
In matched analyses, the relative risks (RR) of CHD for the extreme quintiles of the lipid biomarkers were higher for apoB₁₀₀ (RR=4.7 [2.5 to 8.9]) and low levels of HDL-C (RR=4.2 [2.3 to 7.1]), followed by TGs (RR=3.0 [1.7 to 5.3]), LDL-C (RR=2.7 [1.6 to 4.6]), and TC (RR=1.4 [0.9 to 2.3]). Levels of TGs and their association with CHD did not change appreciably in an analysis limited to women who fasted >8 hours before the blood draw (Table 3). The lipid indexes TC/HDL-C, LDL-C/HDL-C, non–HDL-C, and apoB₁₀₀/HDL-C had stronger associations (Q₅ versus Q₁ RR=6.3, 5.1, 5.0, and 6.5, respectively) than single lipid parameters.

View this table: [in this window] [in a new window]   TABLE 3. RRs (95% CI) Estimated of CHD Across Quintiles and 1 SD Increases of Lipid Parameters, Matched Models*

In multivariable models (Figure 1A) adjusted for plasma CRP, homocysteine, and traditional CHD factors, the association of apoB₁₀₀ (Q₅ RR=4.1 [2.0 to 8.3]), low levels of HDL-C (Q₁ RR=2.6 [1.4 to 5.0]), or TG (Q₅ RR=1.9 [1.0 to 3.8]) with CHD risk was attenuated, whereas the association of LDL-C was not (Q₅ RR=3.1 [1.7 to 5.8]). When repeating the analysis without including alcohol intake, which is directly related to HDL-C,¹³ the RR of low HDL-C levels to CHD was 2.9 (1.5 to 5.6) for the extreme quintiles. There was no significant association between TC and CHD (Q₅ RR=1.1 [0.6 to 2.0]).

View larger version (19K): [in this window] [in a new window]   Figure 1. Multivariate-adjusted* RRs estimated of CHD across quintiles and 1-SD increases of lipid parameters. A, Lipid biomarkers. B, Lipid indexes. *Conditional regression (matched by age and smoking), adjusted for CRP (quintiles), homocysteine (quintiles), BMI (25, 25 to 30, 30+ kg/m2), parental MI before age 60 years, hypertension, diabetes, postmenopausal hormone use, physical activity, alcohol intake, and characteristics of blood at return (no problems, >1 day since drawn, moderate hemolysis).

Multivariate RRs associated with 1 SD (mg/dL) increase in the lipid parameters were as follows: apoB₁₀₀ (RR=1.7 [1.4 to 2.1], SD=32), HDL-C (RR=0.6 [0.5 to 0.8], SD=17), LDL-C (RR=1.4 [1.1 to 1.7], SD=36), TC (RR=1.4 [1.1 to 1.6], SD=40), and TGs (RR=1.3 [1.0 to 1.5], SD=80).

Figure 1B illustrates the associations of the lipid indexes in the multivariable models. ApoB₁₀₀/HDL-C (Q₅ RR=4.6 [2.3 to 9.2]), TC/HDL-C (Q₅ RR=4.1 [1.9 to 8.5]), and non–HDL-C (Q₅ RR=4.4 [2.2 to 8.6]) demonstrated stronger associations for the extreme quintiles compared with the LDL-C/HDL-C (Q₅ RR=3.4 [1.7 to 6.8]). RRs associated with 1 SD of lipid indexes were apoB₁₀₀/HDL-C (RR=1.7 [1.4 to 2.1], SD=1.0), TC/HDL-C (RR=1.6 [1.3 to 1.9], SD=1.3), LDL-C/HDL-C (RR=1.5 [1.3 to 1.9], SD=1.0), and non–HDL-C (RR=1.6 [1.3 to 1.9], SD=42 mg/dL).

Residual Contribution of Lipid Parameters to the Prediction of CHD
In the stepwise model adjusted only for age and smoking status (Figure 2a), HDL-C was the primary contributor to the prediction model, raising the ROC from 0.51 to 0.63. The second contributor was apoB₁₀₀, which increased the ROC to 0.66. We repeated the regression with a multivariable model (Figure 2b). In this model, HDL-C remained the primary contributor to the prediction of the model, raising the ROC from 0.69 to 0.70, and LDL-C entered in the second step, raising the ROC to 0.72. Neither apoB₁₀₀ nor TGs provided further information beyond that provided by HDL-C and LDL-C. HDL-C (Figure 2d) but not apoB₁₀₀ (Figure 2c) provided further information to a model in which we forced the other available clinical parameters. All the lipid indices provided a significant contribution to the multivariable intercept. The HDL-C–related ratios, TC/HDL-C, LDL-C/HDL-C, and apoB₁₀₀/HDL-C, raised the ROC from 0.69 to 0.72, and no additional lipid biomarker contributed significantly (Figure 2, e–g). Non–HDL-C (Figure 2h) raised the ROC to 0.71, and the model was further improved by the addition of HDL-C.

View larger version (50K): [in this window] [in a new window]   Figure 2. Residual contribution of lipid parameters to prediction of CHD. *Multivariate model, adjusted for age, smoking (never, past, current), and variables described in Figure 1. Probability values of likelihood ratio tests, compared with previous model.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
We evaluated the efficacy of multiple plasma lipid parameters in predicting future CHD in women during 8 years of follow-up, taking into account a variety of lipid and nonlipid CHD risk factors. In a multivariate model adjusted simultaneously for several lipids, HDL-C appeared to be the primary lipid predictor among postmenopausal women. For clinical practice, using the TC/HDL-C ratio, a single parameter that combines the traditional lipid measurements provides a powerful predictive model independently of several established risk factors.

Our study has several limitations. First, single measurements of lipids may be susceptible to intraindividual variation.^14,15 However, in a reproducibility study among 82 men from the Health Professionals Follow-Up Study, the intraclass correlation coefficients for plasma lipids collected 3 to 4 years apart were >0.7 for all lipids. Second, because we did not have full measurements of apoA-I, we could not assess the suggested^16,17 predictive value of apoB₁₀₀/apoA-I. However, apoA-I did not add additional value over HDL-C in predicting CHD.^18,19 Third, combining fasting and nonfasting TGs could have blurred their potential predictiveness. However, in our study, the TG distributions of fasting and nonfasting participants were similar, suggesting that most of the individuals who reported "nonfasting" actually had little to eat before the blood draw. Moreover, fasting status was one of the matching criteria in our study. Although this cohort is not a random sample of US women, the lipid levels, such as non–HDL-C, for our control group were similar to those in the Third National Health and Nutrition Examination Survey.²⁰ The relative socioeconomic homogeneity of the cohort might reduce the impact of unknown confounders.

The magnitude of RRs across quintiles is dependent on the absolute risk among women in the bottom quintile and on the independent variation of each lipid parameter. Association with CHD with a 1-SD increase might standardize this variation. In Figure 2, we explored the ability of the lipids to discriminate events from nonevents on the background of all other lipids and covariates, an approach that may be more applicable in a clinical context.

LDL-C is believed to be the main atherogenic lipoprotein in the development of atherosclerosis.²¹ On a continuous scale, a 1-SD (32 mg/dL) difference in LDL-C was associated with a 40% increase in risk of CHD. However, using LDL-C level alone to estimate CHD risk among women may not be sufficient. The Framingham study has demonstrated that within a given level of LDL-C, the risk of CHD depends on levels of HDL-C²² and TGs. We found that a 1-SD difference in HDL-C (17 mg/dL) was associated with a 67% increase in CHD over. If we modeled simultaneously standard NCEP¹ cutpoints for HDL-C and LDL-C as dichotomous variables, the RR of CHD in the multivariable model was 1.88 (1.06 to 3.32) for women with HDL-C <40 mg/dL and 1.58 (1.08 to 2.32) for women with LDL-C >130 mg/dL. The RR for HDL-C <40 mg/dL (1.98 [1.11 to 3.54]) was comparable to the RR for LDL-C >160 mg/dL (1.99 [1.28 to 3.1]) when adjusted simultaneously. According to Figure 2, HDL-C rather than LDL-C was the primary discriminator among women, but both values were important in the prediction of CHD.

Adverse changes in lipoprotein profiles occur at the time of menopause.²³ Because our study population is predominantly postmenopausal women in their sixties, our results may not directly relate to other age groups. Cholesteryl ester transfer protein inhibitors,²⁴ fibric acid derivatives, nicotinic acid, HMG-CoA reductase inhibitors, and estrogens increase plasma HDL-C levels,²⁵ as do several lifestyle and dietary factors such as physical activity and moderate alcohol intake.¹³ Therefore, these therapeutic and lifestyle factors may be considered for raising HDL-C among postmenopausal women.

The role of TGs in CHD remains controversial. A meta-analysis suggested that an 89-mg/dL elevation in TGs was associated with a 14% to 37% higher incidence of cardiovascular disease in women.²⁶ In our multivariable models, an 80-mg/dL elevation of TGs was associated with a 30% increase of CHD. However, our results suggest that most of the association of the TGs could be explained by the impact of other risk factors. Because TG was the lipid that was most strongly associated with nonlipid variables, it could be an intermediate factor, or it could be that a part of the attenuation is because of overadjustments with lifestyle factors.

ApoB₁₀₀ was more strongly associated with CHD than LDL-C (Figure 1A). However, its association was no longer significant after accounting for other lipid fractions (Figure 2b). ApoB₁₀₀ is synthesized by the liver and is secreted with VLDL. The number of LDL particles can be estimated by the plasma apoB₁₀₀ concentration, because the half-life of LDL-C particles^27,28 is 9 times that of VLDL and IDL particles. Some have suggested that apoB₁₀₀ is superior to LDL-C for CHD prediction.²⁹ However, we observed that the association of apoB₁₀₀ with CHD was more attenuated by lipid and nonlipid risk factors than was LDL-C.

Non–HDL-C, which includes cholesterol in LDL- and TG-rich lipoproteins, has been identified as a secondary target of therapy in individuals with TG 200 mg/dL.¹ Despite the high correlation between apoB₁₀₀ and non–HDL-C, these parameters reflect different biological entities.³⁰ Thus, non-HDL cholesterol may not be an adequate surrogate for apoB₁₀₀.

Although addition of TC/HDL (Figure 2e) to the multivariable intercept yielded a higher ROC value (0.72) with no need of further additional significant lipid information, addition of TC and HDL-C as separate values (not shown) yielded a lower ROC (0.70), and LDL-C has been entered to this model in the next step (P<0.05), suggesting that using the single TC/HDL ratio might be more informative than its separate values. TC/HDL or other HDL-C–related ratios,³¹ which reflect the proportion of atherogenic to antiatherogenic lipid fractions, appear to be a powerful tool for predicting CHD among postmenopausal women.

	Acknowledgments

 
This study was supported by National Institutes of Health research grants CA-42182 and CA-18293 and a research grant from Merck Research Laboratories. We thank Dr Frank Speizer, the founding principal investigator, and Dr Graham Colditz, the current principal investigator of the National Health Service, for their invaluable contributions. We are indebted to the S. Daniel Abraham International Center for Health and Nutrition, Ben-Gurion University of the Negev, Israel, and the Fulbright foundation for their support of Dr Iris Shai.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.[Free Full Text]

2. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem. 2001; 47: 1579–1596.[Abstract/Free Full Text]

3. Sniderman AD. Counterpoint: to (measure apo) B or not to (measure apo) B: a critique of modern medical decision-making. Clin Chem. 1997; 43: 1310–1314.[Abstract/Free Full Text]

4. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol. 2002; 90: 48i–54i.[Medline] [Order article via Infotrieve]

5. Rose G, Blackburn H. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: World Health Organization; 1982.

6. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984; 119: 837–839.[Free Full Text]

7. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20: 470–475.[Abstract]

8. Stinshoff K, Weisshaar D, Stachler F, et al. Relation between concentration of free glycerol and triglycerides in human sera. Clin Chem. 1977; 23: 1029–1032.[Abstract/Free Full Text]

9. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated a-cyclodextrin. Clin Chem. 1995; 41: 717–723.[Abstract/Free Full Text]

10. Rifai N, Iannotti E, DeAnagelis K, et al. Analytical and clinical performance of a homogenous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg++ method. Clin Chem. 1998; 44: 1242–1250.[Abstract/Free Full Text]

11. Darlington GA, Farewell VT. Regression modelling of HLA haplotype sharing in affected siblings. Biometrics. 1990; 46: 427–434.[CrossRef][Medline] [Order article via Infotrieve]

12. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143: 29–36.[Abstract/Free Full Text]

13. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999; 319: 1523–1528.[Abstract/Free Full Text]

14. Brown SA, Boerwinkle E, Kashanian FK, et al. Variation in concentration of lipids, lipoprotein lipids, and apolipoproteins A-I and B in plasma from healthy women. Clin Chem. 1990; 36: 207–210.[Abstract/Free Full Text]

15. Pai JK, Curhan GC, Cannuscio CC, et al. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem. 2002; 48: 1781–1784.[Free Full Text]

16. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000; 101: 477–484.[Abstract/Free Full Text]

17. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001; 358: 2026–2033.[CrossRef][Medline] [Order article via Infotrieve]

18. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991; 325: 373–381.[Abstract]

19. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001; 104: 1108–1113.[Abstract/Free Full Text]

20. Gardner CD, Winkleby MA, Fortmann SP. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994). Am J Cardiol. 2000; 86: 299–304.[CrossRef][Medline] [Order article via Infotrieve]

21. Gordon T, Castelli WP, Hjortland MP, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977; 62: 707–714.[CrossRef][Medline] [Order article via Infotrieve]

22. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol. 1998; 4 (suppl A): 5A–10A.

23. Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol. 2002; 90: 77i–84i.[Medline] [Order article via Infotrieve]

24. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004; 350: 1505–1515.[Abstract/Free Full Text]

25. Kashyap ML, Tavintharan S, Kamanna VS. Optimal therapy of low levels of high-density lipoprotein-cholesterol. Am J Cardiovasc Drugs. 2003; 3: 53–65.[CrossRef][Medline] [Order article via Infotrieve]

26. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213–219.[Medline] [Order article via Infotrieve]

27. Elovson J, Chatterton JE, Bell GT, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res. 1988; 29: 1461–1473.[Abstract]

28. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis. 1991; 89: 109–116.[CrossRef][Medline] [Order article via Infotrieve]

29. Lamarche B, Moorjani S, Lupien PJ, et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Québec Cardiovascular Study. Circulation. 1996; 94: 273–278.[Abstract/Free Full Text]

30. Veniant MM, Withycombe S, Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe–/– and Ldlr–/– mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1567–1570.[Abstract/Free Full Text]

31. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003; 146: 227–233.[CrossRef][Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				T. Y. Li, A. M. Brennan, N. M. Wedick, C. Mantzoros, N. Rifai, and F. B. Hu Regular Consumption of Nuts Is Associated with a Lower Risk of Cardiovascular Disease in Women with Type 2 Diabetes J. Nutr., July 1, 2009; 139(7): 1333 - 1338. [Abstract] [Full Text] [PDF]

				J. H. Contois, J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, and G. R. Warnick Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices Clin. Chem., March 1, 2009; 55(3): 407 - 419. [Abstract] [Full Text] [PDF]

				J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]

				S. Mora, N. Rifai, J. E. Buring, and P. M Ridker Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Circulation, September 2, 2008; 118(10): 993 - 1001. [Abstract] [Full Text] [PDF]

				Q. Sun, J. Ma, H. Campos, K. M Rexrode, C. M Albert, D. Mozaffarian, and F. B Hu Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction Am. J. Clinical Nutrition, July 1, 2008; 88(1): 216 - 223. [Abstract] [Full Text] [PDF]

				J. J.P. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, et al. Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment Circulation, June 10, 2008; 117(23): 3002 - 3009. [Abstract] [Full Text] [PDF]

				J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]

				J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]

				K. C. Simon, H. Chen, M. Schwarzschild, and A. Ascherio Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease Neurology, October 23, 2007; 69(17): 1688 - 1695. [Abstract] [Full Text] [PDF]

				Q. Sun, J. Ma, H. Campos, and F. B Hu Plasma and erythrocyte biomarkers of dairy fat intake and risk of ischemic heart disease Am. J. Clinical Nutrition, October 1, 2007; 86(4): 929 - 937. [Abstract] [Full Text] [PDF]

				A. Tirosh, A. Rudich, T. Shochat, D. Tekes-Manova, E. Israeli, Y. Henkin, I. Kochba, and I. Shai Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men Ann Intern Med, September 18, 2007; 147(6): 377 - 385. [Abstract] [Full Text] [PDF]

				E. Ingelsson, E. J. Schaefer, J. H. Contois, J. R. McNamara, L. Sullivan, M. J. Keyes, M. J. Pencina, C. Schoonmaker, P. W. F. Wilson, R. B. D'Agostino, et al. Clinical Utility of Different Lipid Measures for Prediction of Coronary Heart Disease in Men and Women JAMA, August 15, 2007; 298(7): 776 - 785. [Abstract] [Full Text] [PDF]

				R. Clarke, J. R. Emberson, S. Parish, A. Palmer, M. Shipley, P. Linksted, P. Sherliker, S. Clark, J. Armitage, A. Fletcher, et al. Cholesterol Fractions and Apolipoproteins as Risk Factors for Heart Disease Mortality in Older Men Arch Intern Med, July 9, 2007; 167(13): 1373 - 1378. [Abstract] [Full Text] [PDF]

				E. Windler, M. Schoffauer, and B.-C. Zyriax The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 136 - 142. [Abstract] [PDF]

				Q. Sun, J. Ma, H. Campos, S. E. Hankinson, J. E. Manson, M. J. Stampfer, K. M. Rexrode, W. C. Willett, and F. B. Hu A Prospective Study of Trans Fatty Acids in Erythrocytes and Risk of Coronary Heart Disease Circulation, April 10, 2007; 115(14): 1858 - 1865. [Abstract] [Full Text] [PDF]

				N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S. M. Boekholdt, K.-T. Khaw, and V. Gudnason Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies Circulation, January 30, 2007; 115(4): 450 - 458. [Abstract] [Full Text] [PDF]

				T. Wu, W. C. Willett, N. Rifai, I. Shai, J. E. Manson, and E. B. Rimm Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 973 - 979. [Abstract] [Full Text] [PDF]

				R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]

				D.C. Chan and G.F. Watts Apolipoproteins as markers and managers of coronary risk QJM, May 1, 2006; 99(5): 277 - 287. [Abstract] [Full Text] [PDF]

				M. A. Denke Weighing in Before the Fight: Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B as the Best Predictor for Coronary Heart Disease and the Best Measure of Therapy Circulation, November 29, 2005; 112(22): 3368 - 3370. [Full Text] [PDF]

				T. Pischon, C. J. Girman, F. M. Sacks, N. Rifai, M. J. Stampfer, and E. B. Rimm Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men Circulation, November 29, 2005; 112(22): 3375 - 3383. [Abstract] [Full Text] [PDF]

				P. M Ridker, N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women JAMA, July 20, 2005; 294(3): 326 - 333. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/18/2824    most recent 01.CIR.0000146339.57154.9Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shai, I. Articles by Ma, J. Search for Related Content PubMed PubMed Citation Articles by Shai, I. Articles by Ma, J. Related Collections Lipids Risk Factors Epidemiology